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Introduction  
 
 
What is Cancer?   
 
 Our bodies are able to renew and repair themselves, but when the 
mechanisms that control these processes are defective or not working, cancer can 
develop.  Cancer, in simplest terms, is a disease of tissue renewal.  Tissue 
involution and tissue expansion are controlled by various cellular processes and 
when the balance of these processes is disturbed, disease results.  
Degeneration/involution results when cell losses exceed renewal.  Tissue 
expansion, hyperplasia, or neoplasia result when cell renewal exceeds cell losses 
(Pelengaris et al., 2006).  Cancer cells are defined by two properties:  genetic 
alterations allow them to divide and survive when they should not, and they 
invade and colonize areas reserved for other cells.   
Cancer cells clustered together in a mass are called tumors and two types 
of tumors result from tissue expansion.  A benign tumor proliferates, does not 
invade surrounding tissues, and can usually be removed cleanly.  A malignant 
tumor proliferates, invades surrounding tissue, and spreads to distant sites.  
Malignant tumors break from the primary tumor, enter the bloodstream or 
lymphatic vessels, and form secondary tumors called metastases (Alberts et al., 
2004).  Genetic instability of cancer cells leads to an accumulation of mutations.  
These accumulating mutations cause the developing cancer cells to progress 
toward increasing abnormality.  These mutations usually occur over a period of 
many years, which is why cancer is typically a disease of old age.   
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 People fear being diagnosed with cancer.  Early diagnosis and removal of 
the tumor before it has invaded provide the best hope for cure.  Once cancer 
begins to spread, chemotherapy and radiation provide palliative, and sometimes 
curative, therapy.  Initially, therapies can provide positive effects, but the cancer 
can recur when a tumor becomes drug-resistant.  We have to be able to 
understand regulating cell growth in order to be able to control tumor growth and 
improve out ability to treat these diseases.   
 
Cancer Cells 
 Cancer cells have several key abnormalities.  They have a reduced 
dependence on signals from other cells, usually due to mutations in the cell 
signaling pathways.  Cancer cells are unlikely to kill themselves by apoptosis 
because of mutations in the genes that regulate the intracellular death program.  
When the DNA of a normal cell is damaged, a checkpoint mechanism causes it to 
stop dividing until the damaged DNA is repaired.  If the DNA damage is not 
repaired the cell is programmed to die by apoptosis.  This, and other checkpoint 
mechanisms, are defective in cancer cells.   
Furthermore, cancer cells proliferate indefinitely.  Normal cells divide a 
limited number of times because the telomeres on the ends of their chromosomes 
become too short.  Cancer cells, however, reactivate the production of the 
telomerase enzyme, which maintains telomere length, so they can divide 
indefinitely.  Because they are genetically unstable, cancer cells have a greatly 
increased mutation rate.  They are also abnormally invasive because they lack 
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cadherins, or other specific cell-adhesion molecules, that hold normal cells in 
their place.  Finally, cancer cells form metastases by surviving and proliferating in 
foreign tissues, whereas most normal cells die when they are misplaced (Alberts 
et al., 2004).   
We think that cancer cells may be showing loss of actin microfilament 
check-point control of entry into the cell cycle similar to what is seen with yeast 
mutants.  Cancer cells may lack morphological and geometrical controls that 
prevent normal cells from entering the cell cycle if their size, shape, and 
attachments to basement membrane or other supporting growth surfaces are not 
correct.  Indeed, one characteristic morphological phenotype of cancer cells is 
their ability to grow in suspension medium or in semi-solid medium under 
conditions which normal cells will not grow.  Another characteristic feature of 
cancer cells in culture is their loss of density-dependent inhibition of cell division, 
a property called contact-inhibition of cell division.  Cancer cells will continue to 
divide even when in a confluent layer and will pile up on one another making a 
transformed colony of cells.  Normal cells do not exhibit this behavior.  Normal 
cells will divide when seeded in dilute concentration on a surface, but will stop 
dividing when they contact each other.  
Normal mammalian cells, like yeast cells, show behavior that is mediated 
by cell morphology presumably linked to the cell cytoskeleton.  Mammalian 
cancer cells may, like mutant yeast cells, exhibit defects in these morphological 
controls of cell behavior.  Two key morphological features of cancer cells are (1) 
they exhibit loss of density-dependent inhibition of cell division when they reach 
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confluency in monolayer culture.  They continue to divide, even though they are 
no longer in contact with the growth substratum, forming foci of over-lapping 
cancer cell nodules.  (2) They exhibit loss of contact inhibition of cell migration 
allowing them not only to continue to divide when they contact one another, but 
also to continue to migrate even though they are in confluent contact with one 
another.  These are characteristic morphological features of the transformed 
phenotype.  In the section that follows: Potential Actin-Mediated Morphological 
Check-point Control of Cell Cycle Entry, I will elaborate in detail on the 
morphological checkpoint control features of cancer cells that we propose are the 
basis for the effects of microfilament-directed agents on cancer cells that cause 
them to behave differently than normal cells when their actin cytoskeleton is 
disrupted. 
 Over a hundred genes have been identified that can change normal tissue 
into cancerous tissue.  Oncogenes, the dominant transforming genes, encode 
proteins involved in signal transduction and/or cell cycle regulation.  An 
oncogene is an over-expressed and altered form of the normal cellular gene called 
a proto-oncogene.  It has dominant transforming properties, in that a single copy 
of the altered sequence can transform a cell, even in the presence of a normal 
copy of the proto-oncogene (McKinnell et al., 1998).  Proto-oncogenes encode 
proteins that are involved in signaling cascades and, along with oncogenes, are 
classified according to their functional role, either as growth factors, receptors, 
tyrosine kinases, apoptosis pathway regulators, GTP-binding proteins, 
serine/threonine kinases, or nuclear proteins/transcription factors.   
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Normal cells surrounding initiated cells may suppress the outgrowth of the 
cell containing the oncogene.  When a tumor cell and a normal cell are fused, the 
hybrid cell usually exhibits a normal phenotype demonstrating the presence of a 
dominant tumor suppressor gene in the normal cell that is absent or non-
functional in the transformed cell.  Suppressor genes within a normal cell encode 
proteins that negatively regulate cell growth and also function in signal 
transduction and cell cycle regulation.  Some tumor suppressors guard the cell 
against DNA damage and help repair the damage before the cell divides.  Tumor 
suppressors can arrest growth at the first gap phase (G1) and at the second gap 
phase (G2) of the cell cycle.  The integrity of the chromosomes is checked at these 
points before the cell proceeds into DNA replication (S phase) or mitosis (M 
phase) (Alberts et al., 2004).  When tumor suppressor function is lost, these 
checkpoints do not function correctly and cells with damaged DNA can survive 
and can enter the cell cycle to replicate and amplify the genetic anomalies. 
 Hundreds of different tumor types arise from almost every tissue and 
every organ in the body, making it very complicated to classify cancers.  The fact 
that cancer cells show progressive changes toward increasing malignancy and can 
invade and metastasize to distant organs further complicates the issue.  Cancer 
biologists and oncologists have determined a classification system based on the 
tissue of origin, regardless of organ location.  Carcinomas originate from 
epithelial cells and typically represent over 80% of diagnosed human cancers.  
Sarcomas originate in the bone, cartilage, fat, muscle or other connective tissue.  
Lymphomas and leukemias originate from hematopoietic stem cells that generate 
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differentiated cells important in the blood including cells of the immune system.  
Our lab focuses on leukemias, which are cancers that originate in blood-forming 
tissues, like the bone marrow, and cause large numbers of abnormal blood cells to 
be produced (Pelengaris et al., 2006).  Leukemias secondarily involve the spleen, 
lymph nodes, and liver.  Normal hematopoietic elements are displaced from the 
marrow by leukemia cells.  Leukemia cells then spread and the final reserves for 
producing functional hematopoietic elements are lost.     
 
Potential Actin-Mediated Morphological Check-Point Control of Cell Cycle Entry 
 Daniel Lew has discovered a morphogenesis checkpoint in yeast cells that 
monitors the actin cytoskeleton (Lew et al., 1998; Lew, 2000).  It implies that 
spatial and geometric physical controls, not just chemical signal controls, regulate 
normal cell biology.  This morphological checkpoint control of cell cycle 
progression in yeast may relate to observations in neoplastic cells.  Checkpoint 
controls, as I have mentioned, monitor cell cycle events and delay cell cycle 
progression if the events are not completed (Lew et al., 1998).  Lew found that 
when the actin cytoskeleton is perturbed, a morphogenesis checkpoint delays 
nuclear division and bud formation.  Bud formation requires a polarized actin 
cytoskeleton and the delay occurs until a bud is formed.  The cell cycle pauses in 
G2 until the actin can polarize and form a bud (Lew, 2000).   
This delay in bud formation along with the cell cycle progression delay 
prevents the formation of multinucleated cells by monitoring the integrity and 
organization of the actin cytoskeleton (Lew, 1998).  Yeast that are mutant for 
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morphogenetic checkpoint functions, like neoplastic cells, do not recognize the 
actin perturbation and do not exit the cell cycle like normal yeast cells and normal 
mammalian cells.  Instead, they continue to divide and become multinucleated.  
This could imply that if this morphological checkpoint control also functions in 
mammalian cells, then there might be a mutation in this morphogenesis pathway 
in mammalian neoplastic cells.   
 There is evidence to support mechanisms that monitor actin cytoskeleton 
integrity and organization in cells other than yeast cells.  Treisman et al. (2003), 
have discovered a transcription-modulation pathway whose regulation is 
controlled by the availability of monomeric actin in mammalian cells.  
Unpolymerized actin binds directly to a transcription cofactor in this pathway 
(Lew et al., 2003).  Serum response factor (SRF) is a transcription factor that 
controls growth-factor-regulated immediate-early (IE) genes, like cytoskeletal 
actin, and numerous muscle-specific genes.  Studies revealed that SRF and actin 
polymerization have a close connection and that actin is directly involved in the 
signaling pathway of SRF (Treisman et al., 2002).  
Treisman et al. (2003) studied the signaling to SRF via actin.  Activated 
Rho GTPases regulate SRF by their ability to induce actin polymerization by two 
effector pathways:  the ROCK-LIM kinase-cofilin effector pathway that stabilizes 
F actin (Geneste et al., 2002) and the mDia1 effector pathway that promotes its 
assembly.  ROCK is a Rho-dependent kinase, LIM is an actin binding kinase, and 
mDia1 is a diaphanous-related formin protein involved in cytokinesis (Treisman 
et al., 2002).  Rho-actin signaling controls the localization of the SRF coactivator 
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MAL (Treisman et al., 2003).  MAL stands for megacaryocytic acute leukemia 
protein and is a transcription factor.  Responding to Rho-induced actin 
polymerization, MAL is redistributed from the cytoplasm to the nucleus and 
associates with unpolymerized actin through its conserved amino terminal RPEL 
(Arginine, Proline, Glutamic Acid, Leucine) motifs (Treisman et al., 2003).  It 
then binds to SRF and induces gene activation.  Figure 1 shows the ROCK-LIM 
and mDia1 effector pathways involving actin.     
 
Figure 1:  The ROCK-LIM and mDia1 effector pathways involving actin.  
Source:  Treisman, R., Miralles, F., Posern, G., & Zaromytidou, A. (2003).  
Actin Dynamics Control SRF Activity by Regulation of Its Coactivator MAL.  
The Journal of Cell Biology, 113, 340. 
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An important aspect of this signaling pathway that ties into my research is 
related to the inactivation of SRF.  SRF inactivation reduces the response of 
immediate-early gene functions associated with this pathway, like actin, and 
muscle-specific gene expression, which alters cell adhesive properties and causes 
a non-cell-autonomous gastrulation defect (Treisman et al., 2003).  For this 
reason, Treisman et al. (2003) believe that a specific set of SRF target genes that 
are involved in cell morphology, adhesion, and movement are controlled by MAL 
signaling.  In my research, when the actin cytoskeleton microfilaments of human 
neoplastic cells are disrupted with Cytochalasin B and therefore become enlarged 
and multinucleated, it is possible that SRF is inactivated because of the defect in 
this pathway and therefore the target genes are not activated properly.  This could 
contribute or cause the properties of multinucleation and lack of cell adhesion 
seen in the neoplastic cells when their actin cytoskeleton is disrupted with 
microfilament-directed agents such as cytochalasins or latrunculins.  Normal 
mononucleated cells have no defects in the MAL signaling pathway.   
Some of the GTPases involved in, or parallel to, the MAL signaling 
pathway may be a family of guanine nucleotide binding proteins called septins.  
Septins are GTPases required for cytokinesis.  Loss of septin function results in 
multinucleation (Kinoshita et al., 2002).  Septin’s nature is uncertain, but it is 
believed to be an essential filament beneath the cleavage furrow to ensure 
cytokinesis completion (Kinoshita et al., 2002).  Kinoshita et al. found that septins 
may be required for normal actin organization.  They also found that septins play 
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a role in other cellular processes including exocytosis, apoptosis, leukemogenesis 
and carcinogenesis, and neurodegeneration (Kinoshita et al., 2002).   
Osaka et al. (1999) found that the gene designated as MLL is frequently 
rearranged in patients with mixed-lineage leukemia who have been treated with 
topoisomerase II inhibitors.  Using cDNA from the cells of a leukemia patient, 
they found the cDNA to code for another member of the septin family, which they 
named megakaryocyte stimulating factor, or MSF.  Analyzing MSF further may 
help to determine the function of MLL partner genes in leukemia (Osaka et al., 
1999).  Other studies have found that the MLL septin-like fusion gene, MSF, also 
plays a role in breast and ovarian cancers (Kalikin et al., 2000 and Russell et al., 
2000). 
 
Cytochalasin B 
 Our lab’s focus is on exploiting enlarged multinucleated leukemia cells 
that are produced when leukemia cells are treated with microfilament directed 
agents, specifically with Cytochalasin B.  We propose that enlarged 
multinucleated cells may be particularly susceptible to therapy, either by damage 
to their excess nuclei using DNA-directed anti-neoplastic agents or X-Ray, or by 
damage induced by physical challenges such as hypotonicity, ultra-sound, or 
hydrodynamic stress.  We produce enlarged multinucleated leukemia cells using 
Cytochalasin B, which is a pharmacological agent, produced by the fungus 
Helminthosporium dematioideum, that disrupts the actin microfilaments in the 
cytoskeleton of cells and thereby inhibits cytokinesis.  Cytochalasin B, or CB, 
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affects a wide variety of transport and motility processes, including cell 
morphology, and it inhibits cell locomotion, cytoplasmic streaming, blood clot 
retraction, cytokinesis, and axonal growth cone activity (Lin et al., 1978).  
 The destruction of actin-microfilaments inhibits cell movement.  CB caps 
the barbed end of growing actin microfilaments causing a decrease in actin 
polymerization, and changes the morphology of actin filaments in any cell.  It is 
also possible that CB inhibits movement by acting on some other cell component 
(Lin et al., 1973).  To identify and characterize the receptors of the drug, a study 
was done by Lin, Santi, and Spudich, in which they developed an easy procedure 
for preparing [
3
H]cytochalasin B of high specific activity.  The initial studies 
showed the binding of this [
3
H]cytochalasin B to a variety of cell types.  Human 
neoplastic glial cells treated with medium containing 10
-5
 M CB for one hour 
changed from the normal form to a stellate shape, but the effect was fully 
reversible.  Within an hour after removal of CB, the glial cells returned to their 
normal condition (Lin et al., 1973).  Cytochalasin B has rapid and reversible 
effects at the concentration range of 100nM and 10uM in numerous biological 
systems.   
 Cytokinesis is the process by which the cytoplasm is cleaved in two.  It 
begins in anaphase but finishes only after two daughter nuclei have been formed.  
Cytokinesis involves the actin filaments of the contractile ring, which divide the 
cell in two.  The cleavage furrow of the plasma membrane is formed by the action 
of the contractile ring underneath it.  Cytochalasin B disrupts cytokinesis, by 
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inhibiting the formation of the contractile ring.  The cleavage furrow therefore 
does not form and the cell does divide.   
Frank O’Neill (1975) discovered that human normal and malignant cells 
respond to Cytochalasin B differently.  Cancer cells with a disrupted actin 
cytoskeleton continue to produce nuclei and they become multinucleated and 
grossly enlarged, because they cannot complete cell division.  Normal cells do not 
become enlarged and multinucleated when the actin cytoskeleton is damaged, but, 
rather, exit the cell cycle and enter a resting state until microfilament integrity is 
restored.  Treatment of cells with CB can result in some reduction in viability, but 
the effects of CB are reversible, especially for normal cells (O’Neill, 1975).  This 
reversibility of the effects of CB may allow surviving viable cells to return to their 
condition prior to CB treatment after the CB is no longer present.  Thus surviving 
CB-treated cancer cells may retain the capacity to return to their pre-treatment 
state and retain their pathogenic potential.  Asaga et al. (1983) echoed this result 
in work they did involving tumor cells and CB treatment.  They discovered that 
polynuclear cells increased in all cancer cases when Cytochalasin B was applied 
to the cultures.  They saw very little increase in polynuclear cells in benign tumor 
and normal mammary gland cultures (Asaga et al., 1983).       
 Using the observations and previous research done on Cytochalasin B, our 
lab is using CB on U937 human promyelocytic leukemia cells to induce 
multinucleation.  We postulate that multinucleated cancer cells produced by 
treatment with CB will enter apoptosis when exposed to X-ray or to DNA-
directed anti-cancer agents because they will have more nuclei, and therefore 
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more DNA targets: They can have four to eight or more targets as opposed to one 
(See Figures 2 and 3).  In addition, multinucleated cells are bigger and may be 
more fragile and easier to kill than mononucleated cells because of that increased  
 
 
 
cell volume.     
U937 human promyelocytic leukemia cells are used in this work because 
the cells grow in suspension culture.  Since they do not form aggregates or adhere 
to the culture flasks, they can be easily and accurately counted and sized in a 
Beckman-Coulter Particle Counter and in a hemocytometer. This makes it easy to 
determine cell size and number.  We propose that the microfilament-controlled 
difference in cell cycle entry between neoplastic and normal cells can be exploited 
as an approach to therapy based on chemical and physical challenges to enlarged 
multinucleated cells.  We propose further that normal cells that have been induced 
to exit the cell cycle and to enter a resting state will be protected from cell cycle 
Figures 2 and 3:  Mononucleated Human Myelocytic Leukemia Cells 
(Figure 2) and Enlarged, Multinucleated Human Myelocytic 
Leukemia Cells (Figure 3) 
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specific anti-neoplastic treatment protocols, and will not be affected by challenges 
based on increased cell size and multinucleation.   
 
Identification of Properties of Single Cells:  As Populations or As Individuals 
In order to determine whether enlarged multinucleated cancer cells have 
increased sensitivity to damage by physical or chemical challenges, it is necessary 
to be able to determine quantitatively whether the enlarged cells are being 
selectively damaged in the presence of normal-sized mononucleated cells.  It is 
also necessary to establish that at least some of the enlarged multinucleated cells 
remain viable and clonogenic and therefore remain a target to chemotherapy.  We 
must be able to separate the enlarged multinucleated cells from the 
mononucleated cells as populations, or alternatively we must be able to monitor 
the fate of individual enlarged multinucleated cells by microscopic analysis.  
Work by Gold et al. (2006), deals with physical separation of populations 
of enlarged multinucleated human leukemia cells from mononucleated normal-
sized leukemia cells.  Physical separation of large and small cells is needed to 
determine the differential chemical and physical response of enlarged, 
multinucleated cells in comparison with non-enlarged mononucleated leukemia 
cells.  A filter system was devised using a 19um nickel porated sieve to separate 
enlarged cells greater than 19um in diameter from normal leukemia cells with 
diameters of 15um.  The cells were allowed to settle through a 3.5 inch diameter 
19um nickel-porated sieve with no hydrostatic head and no fluid flow through the 
filter.  Cell distribution sizes were determined with a Coulter Counter, and the 
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viability was determined by hemocytometer counts, re-growth assays, and cloning 
assays in agarose.   
Gold et al. (2006) used the purified cells separated from the sieve to test 
the susceptibility of the cells to damage by ultrasound.  In their experiments, they 
sought to determine whether there was a sonic sensitivity in cells treated with 
cytochalasin B that can lead to cell disruption and cell death because CB-treated 
cells were grossly enlarged.  Exposing both CB-treated and control U937 
leukemia cells to ultrasound showed that at identical lengths and intensity of sonic 
exposure, the CB-treated cells are more damaged than the control cells.  They also 
found that there was a statistically significant retardation in growth rate of 
sonicated CB-treated cells two and six days after sonication.  Control cells did not 
show this same response to the ultrasound.  In leukemia treatment, this may 
introduce ultrasound as a physical treatment modality.  However, even in 
separated CB-treated U937 leukemia cells, non-enlarged cells remain at a level of 
5%, and in unseparated CB-treated cells the small cells may range from 15% to 
35% of the total.  Thus, it becomes important to be able to distinguish the 
behavior of enlarged cells in the presence of non-enlarged cells.      
 Work presented here complements work done by Gold et al. (2006), and 
develops methods for observing the reproductive viability of individual leukemia 
cells either by limiting dilution assay and growth of single isolated identified cells 
in suspension culture, or by cloning assay of single identifiable cells fixed in place 
in semi-solid medium.  Monitoring the growth of individual cells in suspension 
culture allows us to determine by dye-reduction assay the number of viable cells 
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that a single cell can produce in a given time.  Cloning of individual identified 
cells in semi-solid medium allows us to determine whether an observed cell is 
able to clone, and if so, the type of hematopoietic clone that the cell produces, 
whether undifferentiated myeloid, or partially differentiated granulocytic, 
monocytic, or erythroid.  A clone is defined as a cell that is identical to the parent 
that produced it, but a clone also has to be defined by some designation of how 
many cells constitute it.  A little clump of 8 or 16 cells is not a clone because it 
means that a cell divided only 4 times before stopping. Usually one 
defines a clone as having 50 or more cells. 
Based off of preliminary studies determined by Dr. Fondy, it has been 
concluded that U937 cells are treated with CB under conditions that convert more 
than 65% of the cells to the enlarged multinucleated state (1.5um CB, 36 to 48 
hours, 20% Iscove’s medium).  CB-treated enlarged multinucleated U937 cells 
retain a cloning efficiency in agarose of 9% to 15%.  Since these cells contain 
from 15% to 35% small cells, and the cloning efficiency of untreated U937 cells 
is 50% to 70%, CB treatment does lower the cloning efficiency.  We need to 
determine whether some of the enlarged multinucleated CB-treated cell remain 
clonogenic and, if so, what proportion of the clonogenic cells seen in the CB-
treated population are enlarged and multinucleated cells.  Figure 4 shows the size 
progression of U937 cells after CB treatment for two days, three days, and four 
days.  Treating cells with CB causes a size shift from 13u all the way up to 45um 
after four days of treatment, showing the extent to which CB can enlarge cells.  A 
                                                                                                                       17 
cell that is 45u in diameter is 27 times larger in volume then the original cell that 
is 15u in diameter.    
 
 
In order to determine whether the enlarged multinucleated cells remain 
viable and potentially pathogenic by direct microscopic observation, the behavior 
of the enlarged cells must be measurable in the presence of normal non-enlarged 
leukemia cells.  We must be able to look at the fate of individual cells.  If the 
enlarged multinucleated U937 leukemia cells remain viable, clonogenic, and 
potentially pathogenic, the cells would be important targets for new approaches to 
therapy directed toward enlarged multinucleated cancer cells.  
Figure 4:  U937 Cell Diameters after CB-treatment for 2 days, 3 days, and 
4 days 
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Looking at individual cells allows us to determine whether enlarged 
leukemia cells retain clonogenic potential and allows us also to determine the 
proportion of enlarged cells that retain clonogenicity.  We are also able to 
correlate cell size with clonogenic potential to determine whether there is a 
relationship between the diameter of the seeded cells and their ability to clone in 
agarose.  The types of hematopoietic cell clones that are formed in agarose are 
also established in order to determine whether differentiation of the U937 
promyelocytic leukemia cells toward erythrocytic, granulocytic, or monocytic 
lineages is affected by CB-treatment.  
My work specifically looks to see whether individually identified enlarged 
cells or small cells treated with CB are cloning.  Enlarged cells are multinucleated 
cells and small cells are mononucleated cells.  I want to determine the 
clonogenicity of the enlarged cells so we can see the correlation between 
multinucleation and cloning.  It is also necessary to determine the fate of 
individual cells in order to determine quantitatively whether the enlarged cells are 
being selectively damaged in the presence of normal-sized mononucleated cells 
when treatments such as sonication are carried out.  My work determines what 
proportion of the enlarged, multinucleated cells are clonogenic.  The more clones 
there are, the more viable the cells are, and the more important they are as 
potential therapeutic targets.   
If the enlarged multinucleated CB-treated leukemia cells retain a 
significant cloning efficiency, they are potential targets for therapy by chemical or 
physical agents.  Work done by Fondy et al. (1990), demonstrated the effects of 
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CB in vivo.  They found that CB administered subcutaneously at 100mg/kg delays 
the time of tumor appearance, inhibits tumor growth rate, and prolongs host 
survival in B16F10 melanoma and M109 lung carcinoma in subcutaneous tumor 
challenge.  This shows that CB does work as a therapeutic agent in mouse cancer 
model systems.  My work points to ways to improve the pre-clinical efficacy of 
CB by focusing attention on enlarged CB-treated cancer cells in the treated animal 
that remain potentially pathogenic and that may be susceptible to killing by other 
therapeutic treatments such as X-ray, DNA-directed anti-neoplastic agents, 
microtubule-directed agents, sonication, and other physically directed therapies.    
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Materials 
 
Fluoresbrite
TM
 Plain YG 20.0 Micron Microspheres 
BioWhittaker
®
 Phosphate Buffered Saline (PBS) 
U937 Human Promyelocytic Leukemia Cells 
Atlanta Biologicals 20% Fetal Bovine Serum in Iscove’s Medium 
Cytochalasin B 
Sigma
®
 Trypan Blue Solution (0.4%) 
Model Z1 Beckman-Coulter Particle Counter 
Hemocytometer 
Reichert Inverted Light Microscope 
MICROTEST
TM
 96-Well Assay Plate, Optilux
TM
 
Millipore Milli Wrap 
Falcon
®
 50mL Tissue Culture Flask 
Forma Scientific Incubator 
SeaPlaque
®
 Agarose 
 
 
Methods 
 
Sterilization and Sizing of 20 u Polystyrene Fluorescent Beads 
 In order to determine the actual range of size distribution of the normally 
20u polystyrene fluorescent beads, the beads were counted and sized using the 
Beckman-Coulter Particle Counter.  Dr. Thomas Fondy counted the beads at 2. 2 
x 10
6
 beads/ml in water as received.  Seven hundred and fifty microliters of bead 
suspension were autoclaved and diluted into 1.5ml sterile PBS (1:3 dilution).  The 
beads were counted as 3.7 x 10
5
 beads/ml and diluted 1:4 in sterile PBS to give 
approximately 1 x 10
5
 beads/ml.  Hemocytometer counts gave 1.7 x 10
5
 beads/ml.  
The Coulter counts and sizing gave 9 x 10
4
 beads/ml.   
 
Enlarging U937 Leukemia Cells with Cytochalasin B 
 U937 human promyelocytic leukemia cells were seeded at  5.0 x 10
4 
viable cells/ml in 20% fetal bovine serum in Iscove’s medium that has 2% by 
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volume of 10,000 units/ml penicillin and 10mg/ml streptomycin, 0.5% gentamicin 
sulfate, and 2mM glutamine.  The U937 cells were treated with 1.25 uM to 2.0 
uM concentrations of Cytochalasin B, for 36 to 48 hours, or two cell cycles. 
These conditions were chosen because they virtually stop cell proliferation, 
allowing the cells to enlarge and multinucleate.  CB-treated U937 cells retain 5% 
to 30% cloning efficiency depending on CB concentration, time of exposure and 
serum concentration.  Trypan blue dye exclusion was used to determine viability.  
Model Z1 Beckman-Coulter Particle Counter was used to establish the size 
distribution and cell number of the enlarged, multinucleated cells.   
 
Cell Viability Determination 
 Cell viability was determined using a trypan blue dye exclusion test and 
hemocytometer.  The trypan blue dye test was used because it is based on the 
principle that viable cells do not take up the dye whereas non-viable cells do.  
Viable cells have an intact membrane, so they are able to exclude the dye, 
whereas non-viable cells lack an intact membrane and take up the trypan blue.  
Fifty microliters of cell suspension and 50ul of 0.4% Trypan Blue stain in isotonic 
saline were mixed and the mixture was transferred to each of the two 
hemocytometer counting chambers.  Under a light microscope using a ruled 
eyepiece reticle or by gauging size seen by comparison with hemocytometer 
markings, the cells were scored as either small (<19u) or big (>19u), and for 
viability.  The total percent viability and cell sizes were determined for the 
population.  The full spectrum of cell sizes was determined with a Beckman 
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Coulter-Particle Counter.  The cells ranged from 13u to 45u in diameter by reticle 
measurement of cells in a hemocytometer using a compound microscope or by 
Beckman-Coulter Particle Counter.     
 
Agarose Cloning in 96-Well Plates 
 
 Distribution of single cells by limiting dilution seeding of wells in a 96-
well plate allows one to identify and measure individual cells and to determine the 
fate of specifically identified cells after growth in suspension medium for twelve 
days.  The concentration of cells and beads in the mixture used to seed the 96-well 
plates determines only the probability that there will be a single cell and five 
beads in any one well.  The polystyrene sterile beads are used to help focus in the 
right microscopic plane and as size standards to help determine whether the cells 
are enlarged cells or small cells.   
There are wells in which no cell is observed, and wells in which up to six 
and even more are occasionally observed.  In cases where a single well is 
observed to have more than one cell at the time of seeding, if that well is observed 
to produce a growing suspension of cells during the cloning assay period, it is not 
possible to determine whether one or more cells were clonogenic and thus it is not 
possible to determine precisely which of the two or more cells was clonogenic.  
However, if the two or more cells in a single well are both (or all) enlarged cells, 
one can conclude that at least one enlarged cell was clonogenic.   
If the positions of the two or more cells in a single well can be fixed by 
seeding the plates with cells and beads in 0.75% agarose medium, the positions of 
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single identified cells can be determined and the clonogenicity of each cell can be 
established.  Furthermore, it is difficult to establish in suspension culture what 
hematopoeitic cell lineage was generated by any clonogenic cell, whereas in 
agarose cloning in culture flasks or 96-well plates this is possible.  Growth of 
U937 leukemia cells in agarose semi-solid medium in test tubes also allows one to 
establish the type of hematopoietic clone that is produced by observing the 
physical characteristics of the clones formed.  However, in test tubes it is not 
possible to determine at the time the agarose tubes are seeded with cells the size 
of the cell that produces a clone after twelve days.  In order to combine the 
advantages of growth in individual wells with the ability to identify a final clonal 
lineage, the methods of seeding in agarose suspension medium and cloning in 
culture flasks and 96-well plates were combined. 
 
CB-Treated Cells Seeded in 96-Well Plates in Agarose with Centrifugation 
 When seeding 96-well plates with beads and cells in agarose, the beads 
and cells are not always in the same microscopic plane.  This experiment spins the 
plate in a Beckman centrifuge to see if all contents in the agarose will settle to the 
bottom plane.   
Ten milliliters of 1.25uM CB Treated U937 cells in 20% FBS at 3 x 10
4
 
viable cells/ml were prepared.  In addition, a preparation of agarose was made 
with 600 cells/ml and 600 beads/ml, which equals 9 cells and 9 beads per 15ul.  
Twenty wells of the inner 60 wells (Rows B and C) of an optically clear plate 
were seeded with 15ul of mixture and allowed to congeal (Rows A and H, the end 
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rows, and columns 1 and 12, the end columns, were not seeded with cells but 
rather were kept empty to allow us to place sterile water and 1% Amphotericin B 
in them to restrict evaporation from the inner 60 wells and trap mold spores 
entering from the outer edges of the plate).  
Another preparation of agarose was made with 50 cells/ml and 50 
beads/ml, which equals 10 cells and 10 beads per 200ul.  Another 20 wells on the 
inner 60 wells (Rows C and E) of the optically clear plate were seeded with 200ul 
of mixture each (10 cells and 10 beads per well).  The plate was immediately spun 
down in the centrifuge to get the cells and beads in Rows B,C,D and E to settle on 
the bottom of the wells.  After centrifugation of the plate, another preparation of 
agarose was made with 9 cells and 9 beads per 15ul.  The remaining 20 inner 
wells (Rows F and G) were seeded with 15ul of contents each and allowed to 
congeal.   
Two hundred microliters of agarose medium were added into each of the 
wells in rows B,C,F and G to bring these volumes to 215ul.  The agarose was 
allowed to congeal and then some of the 60 wells were photographed by inverting 
the plate and viewing the cells near the optically clear bottom.  Two hundred 
microliters of sterile water with Fungizone were added to the outer 36 wells 
(Rows A and H and Columns 1 and 12) and the plate was covered with a gas 
permeable membrane.  The plate was incubated and allowed to clone for two 
weeks.  At the end of two weeks, the plate was scored for wells that cloned in 
reference to the positions of the cells and beads previously identified and 
photographed. 
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Agarose Cloning in 12.5 cm
2
 Flasks: 
 In agarose, cells will not move when cloning.  Therefore, it is possible to 
see exactly which cells cloned.  Cells seeded in agarose medium in 12.5 cm
2
 
culture flasks in a thin layer of agarose become fixed in a single focal plane 
immediately above the optically clear plane of the flasks after the agarose 
congeals.  At that point, the size and position of the seeded cells can be 
determined and recorded.  At the end of the cloning period the position and 
hematopoietic cell lineage of any clone was traced back to whatever cell was 
recorded in that position at the time of agarose cloning.  The daughter cells 
produced by each clonogenic cell will remain at the sites of the stem cell because 
the cells cannot move in semi-solid medium.  This is the advantage of cloning in 
agarose over cloning in liquid medium.  In liquid medium, one must physically 
isolate potentially clonogenic cells from one another by limiting dilution plating 
in microtiter wells or by Live Cell Array slides in order to be able to determine 
the properties of individual source stem cells.        
 Each experiment used three tissue culture flasks.  Two of these flasks 
received 35ul of CB cells and 50ul of beads (500 beads) in 1ml of agarose.  After 
the cells and beads congealed in this layer, 3ml of agarose medium are added to 
each flask and placed in the carefully humidified incubator at 37
o
C for one day to 
allow the agarose to congeal.  If the agarose is not completely congealed, it will 
slide off the edges of the culture flask when inverted, making it impossible to 
score and record the contents.     
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 Day 1 after seeding, the CB-flasks were inverted under the Reichert 
Microscope.  Six fields that were especially rich in big and small cells were 
selected per flask.  The center of each of these fields was marked with a different 
colored sharpie marker.  Using the stage micrometer scale on the microscope, the 
position of each colored mark was recorded and then the pattern of cells and 
beads in each field were recorded using a circular polar graph paper.  The flasks 
were allowed to clone in the incubator at 37
o 
C for two weeks.  After two weeks, 
the flasks were observed under the microscope at their labeled colored marks.  
Positions of the clones were traced to the cells originally in the flasks at the 
positions recorded visually at the time of well-seeding.    
 
Limiting Dilution Assays in 96-Well Plates 
 Limiting dilution assays in 96-well plates allow us to clone cells in liquid 
medium.  Using these methods, one can physically isolate potentially clonogenic 
cells in order to determine the properties of individual source stem cells. 
Enlarged multinucleated U937 cells were diluted to 300 cells/ml in 20% 
FBS Iscove’s medium.  Twenty micron sterile fluorescent beads were added to 
this suspension at 1000 beads/ml.  Five microliters of this mixture were carefully 
placed under sterile conditions into the center of each well in the 96-well optically 
clear bottomed plates, using a Hamilton syringe injector or a 10ul micropipettor.  
This 5ul suspension gave an average of approximately 1.5 cells and 5 beads per 
well.  The plate was inverted under a Reichert Microscope.  The 5ul sample 
remained attached to the inverted optically clear bottom and the well contents 
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were viewed and scored at 56X.  Each well was examined and its bead and cell 
contents were recorded on a 96-well scoring sheet.   As in the agarose cloning, the 
beads help to locate and focus on the bottom of the wells, and to estimate the sizes 
of cells in comparison with the 20u beads.   
 Cells were scored as either “BC” for “big cell,” which is a cell greater 
than 19u, or “SC” for “small cell,” which is a cell smaller than 19u.  Big cells are 
enlarged and multinucleated and small cells are small and mononucleated.  After 
scoring the contents of each well, 195 microliters of 20% FBS Iscove’s medium 
was added to each well, using an 8 track pipettor.  The wells were covered with a 
sterile gas-permeable membrane to reduce evaporation and to prevent mold spores 
from entering the well.   
Typically, three plates were scored for each experiment.  Plate one was 
scored, growth medium was added, and it was incubated before plate two was 
started.  If the cells are left out of medium for too long, they will die, which is 
why it is important to load one plate, score that plate, and add the growth medium 
before starting another plate.  The plates were incubated in a carefully humidified 
incubator at 37
o
C for 12 days, at which point the wells were scored for 
clonogenicity.  The plates were followed for an additional three or four days to 
score weakly clonogenic plates.           
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Results 
Sizing of 20 u Polystyrene Fluorescent Beads 
 After counting and sizing the normally 20u diameter polystyrene 
fluorescent beads with a Beckman-Coulter Particle Counter, it was found that 
10% of the beads are 13u to 18u in size, 72% of the beads are 19u to 23u in size, 
and 18% are 24u to 30u in size.  Figure 5 shows the distribution of these bead size 
counts.  The modal peak is seen around the bead diameter of 23u.   The nominal 
bead size is designated as 20u, but the range of almost equivalent bead 
frequencies is from 20u to 24u (13 to 17% for each of these diameters), with the 
19u and 24u beads each being 10% of the total.   
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 Ninety percent of the beads are 19u or greater in diameter.  When used as 
an index of cell size for cells co-seeded with beads, the size distribution shown in 
Figure 5 allows us to determine that any cell that is equal to or larger than the 
beads when several beads are viewable for comparison must be 19u or larger in 
diameter and thus is an enlarged cell by our criteria.     
 
Agarose Cloning in Flasks 
 Our purpose for seeding the cells in flasks in agarose is to allow us to 
determine the positions of large and small cells after seeding so that if a clone 
appears at a given position in a flask, the size of the source stem cell can be 
established.  The daughter cells produced by each clonogenic cell will remain at 
the site of the stem cell because the cells cannot move in semi-solid medium.  
This is the advantage of cloning in agarose over cloning in liquid medium.  In 
liquid medium, one must physically isolate potentially clonogenic cells from one 
another by limiting dilution plating in microtiter wells or in Live Cell Array 
Slides in order to be able to determine the properties of individual source stem 
cells.   
 I originally tested to see if the cells would clone in agarose when plated in 
a thin layer of agarose in culture flasks.  The seeded cells had to be in a thin co-
planar layer next to the optically viewable surface of the 96-well plate in order to 
be able to see the individual cells and to determine their sizes and record their 
positions.  Colonies of differentiated cells formed in the agarose (See Figures 6 
and 7).  Using images from Stem Cell Technologies manual for comparison, I 
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concluded that a portion of the differentiated colonies are burst forming unit 
erythroid colonies and the remainder are colony forming unit granulocyte 
macrophages.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 6: A large burst-forming unit-erythroid 
differentiated colony that formed in agarose 
 
Figure 7:  A colony forming unit granulocyte, macrophage 
differentiated clonal colony that formed in agarose 
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 In the experiments done cloning CB-treated cells in agarose, a total of 278 
cells were observed in 22 microscopic fields.  The location of each field was 
marked by a different colored marker on the culture flask and, using a circular 
eyepiece reticle, a “map” of cell and bead position was sketched on polar graph 
paper.  Of these fields, three and a half fields had to be discarded because the 
entire field, or half of one field, was covered in clones by the end of two weeks, 
making it impossible to determine which cells individually cloned.   
Excluding the cells from these three and a half fields gives me a new total 
of 218 cells in 18.5 microscopic fields.  Table 1 shows the breakdown of enlarged 
and small cells.  I was working with a population of greater than 80% enlarged 
cells because these cells were previously separated by 19u nickel-porated 
filtration.  Therefore, I was mainly working with cells greater than 19u.  The 
overall cloning efficiency for these experiments in agarose and the cloning 
efficiency of the enlarged cells are unusually high, but using this method, we 
probably are able to see clones that we would otherwise not see in test tubes.   
 
Cells How Many Percentage of 
Population 
Cells that 
Cloned 
Cloning 
Efficiency 
Total 218 100% 82 38% 
Enlarged 208 95% 82 39% 
Small 10 5% 0 0% 
 
 
 
 
Table 1:  Results of Cloning CB-treated U937 Cells in Agarose in Culture 
Flasks 
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CB-Treated Cells Seeded in 96-Well Plates in 15ul Agarose vs. 200ul Agarose 
with Centrifugation 
 When seeding the cells in agarose, the beads and cells end up in different 
planes, unless the beads and cells are seeded initially in a thin layer which is 
overlaid with agarose medium after the initial thin layer has congealed.  Thin 
layer seeding and agarose overlaying are difficult to do in 96-well plates.  For this 
reason, I performed this experiment to find a way to get the beads and cells in the 
same microscopic plane in 96-well plates.  Table 2 shows how the plate was 
divided and loaded.   
Rows Volume Centrifuge Number 
of Wells 
Number 
of cells 
Number 
of 
Clones 
Cloning 
Efficiency 
B and C 15ul Yes 20 100 44 44% 
D and E 200ul Yes 20 100 24 24% 
F and G 15ul No 20 90 36 40% 
 
 
 The cells in this experiment were not originally recorded as being enlarged 
or small because the purpose of this experiment was to show the effects of 
centrifugation and volume of agarose seeded on cloning efficiency.  Table 1 and 
Figure 8 show the cloning efficiencies for the different volumes and with and 
without centrifugation.   
 
 
 
Table 2:  Experiment and Results of Varying Volume with Centrifugation 
and Effects of Centrifugation 
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 I determined that a lower volume of cells and agarose spun down is ideal 
for getting the beads and cells in a single focal plane for viewing and mapping of 
sizes and positions.  The cloning efficiency of the wells with 15ul spun down and 
the wells with 15ul not spun down was very similar (44% compared to 40%), so 
centrifuging the wells does not affect clonogenicity.  Thus, centrifuging puts the 
beads and cells in the same plane, which helps to score the contents, and it does 
not affect the cloning efficiency.  Seeding the cells in 200ul of agarose and 
attempting to centrifuge the cells and beads to the bottom of the wells did not 
work as well in terms of cloning efficiency as did seeding in 15ul (24% compared 
to 44%), even though I saw 100 cells in both cases. 
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Limiting Dilution Assays in 96-Well Plates:  Percentages of Enlarged Cells 
Observed in Wells vs. Percentages of Enlarged Cells in Seeded in Suspension 
 The results of eleven limiting dilution assay experiments will be 
incorporated into the following sections.  In each of these experiments, I 
determined the percentage of enlarged CB-treated cells that I observed in the 
wells by dividing the total number of enlarged cells I recorded seeing in the wells 
by the total number of cells seeded.  Before I seeded the wells, Dr. Fondy 
determined the percentage of enlarged cells that were in the suspension by 
Beckman-Coulter particle counting.  Figure 9 shows the comparison between the 
percentage of enlarged cells that I actually observed in the wells and the 
percentage of enlarged cells that Dr. Fondy determined were in suspension.    
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 My data indicates that I seeded a higher proportion of enlarged CB-treated 
cells in the wells than what Dr. Fondy originally recorded and so I was therefore 
working with a higher population of enlarged cells. This discrepancy means that 
the enlarged and small CB-treated cells were not loaded into the wells or observed 
in the wells in equal proportions either because I was able to see enlarged cells 
more easily by careful microscopic examination or because some small cells may 
be broken up during the seeding operation causing them to be unseen by 
microscopic examination.  If this latter alternative is correct, the missing small 
cells must be damaged and non-viable.  I was working with 94% enlarged cells 
CB-treated cells and 6% small CB-treated cells.  To determine the average of 
enlarged and small cells, I divided the total number of enlarged cells observed in 
the wells by the total number of cells observed in the wells.  To determine the 
average percentage of small cells, I divided the total number of small cells 
observed in the wells by the total number of cells observed in the wells.   
 
Limiting Dilution Assays in 96-Well Plates:  Contents and Cloning Efficiencies of 
Total Cells  
 Ideally, I aimed to seed one cell per well.  Probabilities dictate that there 
would be some wells with more than one cell and some with no cells.  Some wells 
contained only one cell, other wells contained anywhere from 2 to 5 cells, and 
other wells contained no cells (see Appendix A).  In wells that contained multiple 
cells, I could still draw conclusions if all the cells in the well were enlarged cells 
or, alternatively, if all the cells in the well were small cells.  The difficulty lies in 
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wells that contained mixtures of enlarged and small cells.  If these wells clone, it 
is impossible to determine which size cell was responsible for the cloning, making 
it difficult to draw any conclusions from these wells.  For this reason, a total of 68 
wells had to be excluded because they contained a mixture of enlarged and small 
cells (In the last section of the results, I will discuss the cloning efficiencies of 
enlarged and small cells, including the wells that contained mixed contents).  
Table 3 shows the total number of wells scored and the total number of wells that 
cloned for all experiments, excluding wells that had mixed large and small cells. 
 
Number of 
Plates 
Number of 
Wells 
Number of Wells 
that Cloned 
 
Cloning Efficiency 
16 1,131 100 8.84% 
      
 
 The total number of wells is not a multiple of 96 because wells 
occasionally had to be excluded for mold growth or because the loading sample 
hit the edge of the well.  When the loading aliquot touches the edge of the wells 
rather than remaining as a circular dot in the middle of the wells, it is not possible 
to be certain of whether there are cells that remain unobserved at the interface 
between the sample aliquot and the walls of the wells.   
I determined the cloning efficiency, or clonogenicity, for each experiment 
by dividing the total number of wells that cloned by the total number of wells that 
were scored.  The results and specific cloning efficiency for each experiment and 
Table 3:  Number of Wells Scored and the Average Cloning Efficiency of 
all the Experiments  
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the overall clonogenicity are shown in Figure 10.  The average cloning efficiency 
was found by dividing the total number of wells that cloned by the total number 
of wells that were properly seeded, in this case 100 wells with clones divided by 
1,131 wells properly seeded.  The average cloning efficiency was 9%.  This graph 
shows the variation in cloning efficiencies for each experiment.  I will suggest 
some possible reasons for these variations in my discussion section.   
 
Limiting Dilution Assays in 96-Wells Plates:  Contents of Wells that Cloned 
 In the 100 wells that cloned, 94 contained only enlarged cells.  This means 
that 94% of the wells that cloned contained only big cells, thus demonstrating that 
the enlarged cells are clonogenic.  The remaining 6 wells that that cloned 
contained only small cells.  Figure 11 shows the contents of the wells that cloned 
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for each experiment.  Figure 12 shows the overall contents of the wells that 
cloned.   
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Limiting Dilution Assays in 96-Well Plates:  Lower Limit Cloning Efficiency of 
Enlarged, Multinucleated CB-Treated U937 Cells 
Of the 94 wells containing only enlarged cells that cloned, 33 contained 
only one enlarged cell and the remaining 61 wells contained 2 or more enlarged 
cells.  Thus, we know that at least 94 big cells cloned out of 2,127 big cells in 
1,131 wells, giving a lower limit cloning efficiency of the enlarged cells of 4.4% 
(see Table 4).  It is possible that in some wells with two or more big cells, more 
than one big cell cloned.  However, I am able to establish with certainty that at 
least 4.4% of the CB-treated enlarged U937 leukemia cells remain viable and 
potentially pathogenic after CB treatment.  If these viable, enlarged cells prove to 
be super clonogenic, meaning they produce more than 2 daughter cells because 
they are multinucleated, then they could be extremely pathogenic and strong 
targets for destruction.      
  
Limiting Dilution Assays in 96-Well Plates:  Upper Limit Cloning Efficiency of 
Enlarged, Multinucleated CB-Treated U937 Cells 
 If all the enlarged cells in each of the 61 multiply-loaded wells with big 
cells cloned, then a maximum of 224 enlarged cells cloned out of the 2,127 
enlarged cells seeded.  This would give an upper limit cloning efficiency of 
enlarged cells of 10.5% (see Table 4).  There is a very low chance that more than 
2 enlarged cells per well cloned.  However, this means that the overall cloning 
efficiency range of enlarged, multinucleated U937 cells is 4.4% to 10.5%.  
Whether 4% or 10% of the enlarged CB-treated cells remain viable, the important 
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point to remember is that some of the enlarged cells remain viable and pathogenic 
after CB-treatment and thus are targets for therapeutic destruction.     
 
Limiting Dilution Assays:  Cloning Efficiency of Small U937 Cells in CB-Treated 
Populations 
In the wells containing only small cells that cloned, only one small cell 
was observed in each well, meaning that an upper and lower limit cloning 
efficiency does not need to be determined for the small cells because a range does 
not need to be established.  Thus, in the six wells that cloned containing only 
small cells, a total of 6 small cells cloned.  Of the 46 small cells observed in these 
experiments, the 6 that cloned gives a 13% cloning efficiency for the small, 
mononucleated cells (see Table 4).  This percentage is significantly lower than the 
cloning efficiency of untreated U937 mononucleated leukemia cells, which is 
50% to 70%.  This means that CB treatment is affecting these mononucleated 
cells and they are not simply U937 myeloblastic leukemia cells representative of 
the original population of cells treated with CB.  Figures 13 and 14 show a graph 
distribution of the upper and lower limit cloning efficiencies for the enlarged cells 
and the cloning efficiency of the small cells.  Figure 13 shows a 3D graph of all 
the experiments and Figure 14 shows the overall cloning efficiencies.   
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Case Number of 
Wells 
Number of 
Cells Cloned 
Number of 
Cells Seeded 
Cloning 
Efficiency 
Lower Limit 
for Enlarged 
94 94 Big 2,127 Big 4.4% 
Upper Limit 
for Enlarged 
94 224 Big 2,127 Big 10.5% 
Small 6 6 Small 46 Small 13% 
 
 
 
 
 
Table 4:  Upper and Lower Limit Cloning Efficiencies of Enlarged Cells 
and Cloning Efficiency of Small Cells 
Figure 13: Upper and Lower Limit Cloning Efficiencies of Enlarged
and Small CB-Treated U937 Human Promyelocytic Leukemia Cells
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Limiting Dilution Assays in 96-Well Plates: Cloning Efficiencies for Enlarged and 
Small Cells if Wells That Had Mixtures of Enlarged and Small Cells are Included 
 After scoring the wells, I discovered that 68 wells contained a mix of 
enlarged and small cells.  In the previous calculations determining the cloning 
efficiency of enlarged and small cells, I did not take these wells into account.  
Thirteen of these 68 wells that contained mixes of enlarged and small cells ended 
up cloning, but I cannot conclude which size cells in these wells was responsible 
for the cloning.     
 If I include all the contents of these mixed wells, I end up with a total of 
2,283 enlarged cells and 140 small cells seeded in the wells.  I end up with 
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different cloning efficiencies then for the enlarged and small cells.  Table 5 shows 
these different cloning efficiencies. 
Case Number of 
Wells 
Number of 
Cells Cloned 
Number of 
Cells Seeded 
Cloning 
Efficiency 
Lower Limit 
for Enlarged 
94 94 Big 2,283 Big 4.1% 
Upper Limit 
for Enlarged 
94 224 Big 2,283 Big 9.8% 
Small 6 6 Small 140 Small 4.3% 
 
 The cloning efficiency is barely affected for the enlarged cells; however 
the cloning efficiency of the small cells in quite different.  Far fewer small cells 
were seeded in these experiments and the probability of having a small cell 
seeded in the same well as an enlarged cell was very likely.  Ninety-four of the 
small cells observed were co-seeded in the same well as an enlarged cell.  Only 46 
small cells were in wells by themselves.  Therefore, when I eliminate the wells 
containing mixtures of enlarged and small cells, I am eliminating the majority of 
the small cells.   
 Not only were fewer small cells seeded, but when they were in wells with 
mixed contents, they would sometimes be seen in clusters.  The mixed wells 
therefore had anywhere from one small cell to four small cells, if a cluster was 
formed.  By seeding fewer small cells, if one small cell ends up cloning, it affects 
the overall cloning efficiency much more than if one enlarged cell cloned.  This 
section was included to show that there were more small cells observed in the 
Table 5:  Upper and Lower Limit Cloning Efficiencies of Enlarged Cells 
and Cloning Efficiency of Small Cells Including Cells in Mixed Wells 
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wells, they were just in wells with enlarged cells and I cannot draw definite 
conclusions from these wells.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                       45 
Discussion and Conclusion 
 
Sizing of 20 u Polystyrene Fluorescent Beads 
 In determining the size of the polystyrene fluorescent beads, I confirm that 
they are sufficient to use as a size standard to determine an enlarged cell.  Ninety 
percent of the beads are greater than 19u, and anything over 19u is considered an 
enlarged cell.  Since the average bead size is actually 23u, cells that are equal to 
or larger than the average beads visible in the microscope field are well over 19u 
in diameter.  When determining a “small cell” (a cell less than 19u in diameter), 
however, it is not accurate to say that any cell smaller than any bead is a small 
cell.  Since I seeded anywhere from three to five, and sometimes more, beads per 
well, I would look at the smallest bead in the field to determine a small cell.  If a 
cell was significantly smaller than that smallest bead, I would record it as a small 
cell.  Furthermore, after looking at thousands of cells under the microscope, my 
eyes have a very accurate view of what a small cell looks like and what an 
enlarged cell looks like.   
Overall, the beads are a helpful contributor to determining cell size and 
they are essential for locating the focal plane containing the cells and for focusing 
the microscope fields.  The beads are also valuable size standards to use for 
comparison of cells in photomicrographs done at different camera zoom settings. 
 
Agarose Cloning of CB-Treated Cells in Culture Flasks 
 Although the majority of my work did not focus on agarose cloning, I can 
still make many valuable conclusions from this work.  It has already been 
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established from previous work by Dr. Fondy that untreated U937 cells have a 
cloning efficiency of 50% to 70% when cloned in agarose in test tubes.  I was not 
sure if my methods for cloning CB-treated cells in agarose would be successful.  
However, I was able to establish that CB-treated U937 human myelocytic 
leukemia cells do clone in a thin layer of agarose in culture flasks and they do 
clone in agarose in 96-well plates.  This was important to determine because now 
these methods can be used to monitor the fate of individual cells in agarose by 
close microscopic examination.  Examining contents under a microscope allows 
one to have a closer inspection and see contents that may not have been visible in 
the agarose cloning in test tubes.     
 CB-treated U937 human promyelocytic leukemia cells form differentiated 
colonies in thin layer agarose and in agarose in 96-well plates.  I determined that 
these colonies are large burst-forming unit-erythroid and colony forming unit 
granulocyte macrophage colonies.  Any type of cloning or differentiation seen 
indicates that the cells are still viable and are therefore potential targets for 
destruction.  It may be that CB induces differentiation in U937 human myelocytic 
leukemia cells in agarose, since the untreated U937 cells that cloned in agarose in 
test tubes did not clone into differentiated colonies.  The CB treatment may be 
what is causing the cells to form burst-forming unit-erythroid differentiated 
colonies and colony forming unit granulocyte macrophage differentiated colonies.  
We need to look at untreated U937 cells by these methods to see if CB is what 
induces this differentiation.     
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 Cloning in agarose successfully restricts the cells to one place, unlike 
cloning in liquid medium.  Both the overall cloning efficiency of enlarged and 
small cells combined in agarose (38%) and the separate cloning efficiency of 
enlarged cells alone in agarose (39%) are unusually high.  This may be because 
one sees clones by this method that may not be seen in the test tubes because, as 
previously mentioned, the agarose flask cloning procedures view the clones under 
the microscope.  I count as clones collections of cells that have 5u or more cells.  
Some of these may escape observations in test tubes.  More experiments need to 
be run to compare the cloning efficiencies of the agarose flasks to the cloning 
efficiencies of the agarose tubes.  This would help to explain the high cloning 
efficiencies seen for the CB-treated cells in the flask cloning procedure and also 
help to conclude if one method of cloning actually causes higher clonogenicity.   
 The fact that the CB-treated enlarged cells have a cloning efficiency of 
39% in agarose is a very significant finding.  This means that the enlarged cells 
are still viable and therefore potential targets for destruction after CB treatment.  
The small cells had a cloning efficiency of 0%, but only 10 small cells were 
seeded in the culture flasks, which is too few to make any definite conclusions.  
More CB-treated small cells would need to be seeded and cloned in the agarose 
flasks to see if they truly are not clonogenic.   
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CB-Treated Cells seeded in 96-Well Plates in 15ul Agarose vs 200ul Agarose with 
Centrifugation 
This experiment was done to see if centrifuging the cells affects 
clonogenicity.  When seeding cells in agarose, they end up in multiple 
microscopic planes.  This makes it very difficult to accurately determine all the 
contents in agarose, because it is very easy to miss contents that are in multiple 
focal planes.  Centrifugation should cause all contents in the agarose to go to the 
bottom of the well, making it much easier to visualize the contents and placing 
everything in the same plane.  I needed to determine what initial volume of cells 
would be ideal for centrifuging the cells and beads down into a single plane, and 
also whether centrifuging affected clonogenicity.     
 In this experiment, I determined that an initial volume of 15ul of cells and 
agarose is preferable to an initial volume of 200ul of cells and agarose for 
centrifuging and for looking at the beads and clones.  The cloning efficiencies 
were very different, 44% and 24%, respectively.  The cloning efficiency between 
the wells with 15ul spun down was 44% and the cloning efficiency of the well 
with 15ul not spun down was 40%.  These cloning efficiencies are very similar, so 
centrifuging the wells does not appear to affect clonogenicity.  Centrifuging puts 
the beads and cells in the same plane, which makes scoring the contents of the 
wells both easier and more accurate, and it does not affect the cloning efficiency.   
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Limiting Dilution Assays in 96-Well Plates:  Percentages of Enlarged CB-Treated 
Cells Observed in Wells vs. Percentages of Enlarged CB-Treated Cells Seeded in 
Wells 
 The bulk of my research focused on limiting dilution assays in 96-well 
plates.  For each experiment, I determined the proportion of enlarged CB-treated 
cells I observed in the wells.  Before giving me the cells to work with, Dr. Fondy 
determined the proportion of enlarged CB-treated cells in the cell suspension that 
I used to seed the wells.  My results (see Figure 9) indicate that I observed a 
higher proportion of enlarged cells in the wells than what Dr. Fondy originally 
recorded.  This discrepancy may have arisen because I was able to see more of the 
enlarged cells than the small cells by careful microscopic examination.  The lower 
size limit of small cells for untreated U937 leukemia cells is 13u and we record 
“small cells” measured with the Beckman-Coulter Counter as those cells that 
range between 13u and 18u in diameter.  It is possible that some cells as small as 
13u that are detected with the Beckman-Coulter Counter and are recorded as 
“small cells” in the population of cells used to seed the plates, may escape visual 
observation in the wells.  
Overall, I observed a population of CB-treated cells in the wells that were 
94% large cells and 6 % small cells.  The proportion of large vs. small cells used 
to seed the plates was actually 74%:36%.  My research was specifically focused 
on determining whether the enlarged CB-treated U937 leukemia cells remain 
viable and clonogenic.  The disproportionately high percentage of enlarged cells 
                                                                                                                       50 
seen in the wells does not affect the conclusion that they retain a very significant 
cloning efficiency of approximately 4.5%.  
The disproportionately low percentage of small cells observed in the wells 
may mean that some clonogenicity attributed to enlarged cells could arise from 
unseen small cells.  However, in cases where small cells were observed separate 
from large cells, I was able to determine that the small cells have a very low 
cloning efficiency, so that a few small cells that may escape observation could not 
produce the cloning efficiency of 4.5% seen for the 94% of the cells that are large. 
The fact that I observed differentiated colony-forming units in the CB-treated 
cells cloned in agarose indicates that CB may be inducing differentiation.  Thus 
some or even all of the small cells may in fact be differentiated granulocytes and 
thus would not be clonogenic stem cells. 
 
Limiting Dilution Assays in 96-Well Plates:  Contents and Cloning Efficiencies of 
Total CB-Treated Cells  
 The variability in clonogenicity for the experiments may be related to the 
slight differences in procedures between experiments.  Experiments MF63, MF82, 
MF115, MF126, and MF128 all had slightly higher cloning efficiencies (see 
Figure 11) because the plates were loaded using the micropipettor to load each 
well individually.  Experiments MF116, MF120, MF121, MF123, MF124, and 
MF125 all had lower cloning efficiencies (see Figure 11) because they were 
loaded with the sterile repeating injector and showed more mold contaminated 
wells than did the plates in MF63, MF63, MF82, MF115, MF126, and MF128.    
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The plates that I scored and obtained results from had no more than a 
couple of wells with mold contamination.  The plates that I discarded in these 
experiments were completely covered in mold growth.  For some reason, the 
sterile injector procedure was leading to mold contamination in these wells 
because of the difficulty I had in directing the injector into the wells.  This caused 
the cloning efficiency to be lower in these experiments.  The average cloning 
efficiency for all the experiments was 9% (see Table 3), which is analogous to the 
cloning efficiency Dr. Fondy finds using the test tube method.   
 
Limiting Dilution Assays in 96-Wells Plates:  Contents of Wells that Cloned 
In the wells that cloned, the overwhelming majority contained enlarged 
cells.  This is not surprising, since more wells contained enlarged CB-treated 
cells, but it must be remembered that untreated U937 leukemia cells have a 
cloning efficiency of 50% to 70% and are extremely pathogenic.  Of the 100 wells 
that cloned, 94 contained only enlarged cells and 6 contained only small cells 
(Note:  these numbers are in no way related to the overall percentages of enlarged 
and small CB-treated cells that were seeded [94% enlarged to 6% small].  It is a 
mere coincidence that the two numbers ended up being the same and that an even 
100 wells cloned).  When I compare the proportion of enlarged CB-treated cells 
that cloned to the proportion of small CB-treated cells that cloned, the results are 
remarkable.   
 In the wells that contained multiple enlarged CB-treated cells, I 
determined the upper and lower limit cloning efficiencies.  The upper limit 
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cloning efficiency is the case in which all the enlarged CB-treated cells in these 
wells cloned and the lower limit cloning efficiency is the case in which only one 
enlarged CB-treated cell in these wells cloned.  All of the wells that cloned with 
small cells only contained one small cell, so an upper and lower limit cloning 
efficiency is unnecessary to determine.   
 
Limiting Dilution Assays in 96-Well Plates:  Cloning Efficiency Range of 
Enlarged, Multinucleated CB-Treated U937 Cells 
The enlarged CB-treated cells still have a cloning efficiency that is far 
lower than that of untreated U937 cells (4% to 11% compared to 50% to 70%, 
respectively).  This means that CB-treatment is altering the viability and 
clonogenicity of U937 leukemia cells that disrupt the actin filaments.  If none of 
the enlarged cells were clonogenic after treatment with CB, then it would mean 
that they were dead and not potential targets for destruction.  The CB treatment 
alone would have killed all the pathogenic cells.  The fact that at least some are 
still viable indicates that they can be targets for further treatment leading to 
complete destruction.   
The 4% to 11% (or more in agarose) of these enlarged CB-treated cells 
that remain viable and potentially pathogenic are our targets.  If these cells are 
‘super clonogenic,’ then they have the potential to be extremely pathogenic 
because they are multinucleated and may produce multiple viable daughter cells 
when they divide.  Exposing these viable enlarged, multinucleated CB-treated 
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leukemia cells to sonication or X-radiation, may kill the enlarged cells that remain 
viable.  This could then be used as a therapeutic approach in cancer treatment.  
 
Limiting Dilution Assays:  Cloning Efficiency of Small, Mononucleated U937 
Cells in CB-Treated Populations 
The small, mononucleated CB-treated leukemia cells should have a 50% 
to 70% cloning efficiency if they are simply U937 leukemia cells unaffected by 
Cytochalasin B treatment or if they are U937 cells that were able to successfully 
complete both mitosis and cytokinesis in spite of having disrupted actin 
microfilaments.  The small cells present in the CB-treated population have a 13% 
cloning efficiency, which is significantly lower than the 50%-70% of untreated 
small leukemia cells, indicating that the small CB-treated cells are in some way 
affected by CB treatment.  If they went through the cell cycle and divided without 
being altered, they should be clonogenic.  This means that the small cells seen in 
the CB-treated population could be small cells because they are dead or they 
could be small non-clonogenic cells because they are neutrophils or other types of 
differentiated cells. 
 
Proposed Improvements for Procedures Used in These Experiments 
Some advances and improved techniques can be built off of these methods 
and results.  More experiments need to be run and data needs to be gathered on 
cloning the cells in agarose in each well of a 96-well plate and centrifuging the 
contents down to the same microscopic plane.  I did test this technique by 
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methods I have explained in the work presented above, but have not yet 
performed experiments scoring enlarged cells using this procedure.  Unlike with 
limiting dilution in liquid medium, if more than one cell is seeded in each well in 
agarose then it would be possible to determine which cell was responsible for the 
cloning, as long as the plates were scored before the clones spread throughout the 
entire well.  
 If the limiting dilution assays in the 96-well plates in liquid medium 
method is the preferred method, then it would be necessary to obtain a dilution so 
that there is less than one cell per well.  The dilution I have now, gives 1.5 cells 
per well, but that is not always what is seen.  The dilution would have to be 
calculated to get less than one cell per well.  More plates would have to be seeded 
because more wells would be empty.  There is no guarantee, either, that one 
would seed only one cell per well.  For this reason, a distribution for cloning 
efficiency will always be seen (see Appendix A). 
 Another advancement that could be made would be to determine the size 
of the enlarged cells to see if we can relate enlarged cell size to the degree of 
clonogenicity.  One would be able to determine if there is a correlation between 
cell size and clonogenicity by determining the actual sizes of the cells in the 
wells.  One would be able to tell if an enlarged cell was 22u or 26u, etc. by using 
the circular eyepiece reticle in the Reichert microscope to determine the cell sizes.   
 For more comparison purposes, it would be beneficial to seed equal 
proportions of enlarged and small cells to see how more of the small cells act.  I 
did not work with large proportions of small cells, since that was not the focus of 
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my research, but it would be helpful to gather that data.  I was able to successfully 
work with populations of enlarged, multinucleated cells.  It was important to see 
the way enlarged, multinucleated cells act, but now that data must be expanded 
upon.   
 It would also be important to determine how many nuclei each enlarged 
cell has and how many daughter cells it goes on to produce.  One needs to know if 
a multinucleated cell is initially producing two daughter cells that are initially 
multinucleated after one cytokinesis event or if it producing multiple daughter 
cells that may be mononucleated after multiple simultaneous cytokinesis events.  
These multinucleated cells have the potential of being super clonogenic and it 
needs to be determined if they are producing multiple viable daughter cells.   
 
Proposals for the Therapeutic Treatment of Clonogenic Enlarged Multinucleated 
Leukemia Cells Produced by Cytochalasin B Treatment 
In regards to using Cytochalasin B as a therapeutic agent, a next step 
would be to X-ray or sonicate the neoplastic cells treated with CB and then 
compare the cloning efficiency of these cells to the cloning efficiency of CB 
treated neoplastic cells not X-rayed or sonicated.  X-ray and sonication are two 
ways in which neoplastic cells can be damaged.  If our proposal is correct, the 
CB-treated neoplastic cells exposed to X-ray or sonication will have a lower 
cloning efficiency than the CB-treated cells not exposed to X-ray or sonication.   
 If the proposal that CB treated neoplastic cells exposed to X-ray or 
sonication show a lower cloning efficiency than normal neoplastic cells can be 
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confirmed, this could potentially introduce Cytochalasin B treatment as a 
therapeutic agent in leukemia treatment.  Cytochalasin B treatment, combined 
with the physical and chemical modalities of X-ray and sonication, could enhance 
and increase the cytotoxic effects of microfilament agents in cancer therapy.  This 
work shows the enlarged multinucleated CB-treated U937 cells retain viability 
and clonogenicity when the CB is diluted out and thus remain potentially 
pathogenic and are targets for therapeutic modalities based on increased size and 
multinucleation.     
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Appendices:  Appendix A:  Cell and Bead Distributions for Some Experiments 
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Appendix B:  Data Used to Determine Results. 
 
  
Data used if I excluded wells that contained mixed enlarged and small cells.   
Experiment 
Total 
Wells 
Wells 
cloned 
Cloning 
Efficiency 
# of plates 
scored 
# of enlarged 
cells 
# of small 
cells 
MF63 16 2 12.5 1 8 8 
MF82 99 7 7.07 2 139 6 
MF115 50 15 30 1 66 6 
MF116 289 6 2.08 3 633 1 
MF120 192 10 5.21 2 242 3 
MF121 49 1 2.04 1 102 3 
MF123 68 4 5.88 1 78 10 
MF124 75 4 5.33 1 129 3 
MF125 72 1 1.39 1 185 2 
MF126 60 16 26.67 1 172 2 
MF128 161 34 21.12 2 373 2 
              
Sums 1131 100 8.84 16 2127 46 
 
 
Data used if I included wells that contained mixed enlarged and small cells.   
Experiment 
Total 
Wells 
Wells 
cloned 
Cloning 
Efficiency 
# of plates 
scored 
# of enlarged 
cells 
# of small 
cells 
MF63 16 2 12.5 1 8 8 
MF82 115 11 9.57 2 166 29 
MF115 50 15 30 1 66 6 
MF116 315 7 2.22 3 696 43 
MF120 192 10 5.21 2 242 3 
MF121 55 1 1.82 1 121 10 
MF123 69 4 5.8 1 80 11 
MF124 75 4 5.33 1 129 3 
MF125 74 1 1.35 1 187 5 
MF126 69 21 30.4 1 196 11 
MF128 169 37 21.89 2 392 11 
              
Sums 1199 113 9.42 16 2283 140 
 
 
